Scroll To Top
Health

FDA approves new label information for Sustiva

FDA approves new label information for Sustiva

The Food and Drug Administration on Thursday approved new label information for Bristol-Myers Squibb's HIV nonnucleoside reverse transcriptase inhibitor Sustiva that includes data from a recent clinical trial showing that a Sustiva-based regimen is effective in suppressing HIV replication for at least three years. The clinical trial studied 1,266 previously treatment-naive HIV-positive adults who began a regimen containing Sustiva and various combinations of two other anti-HIV drugs. About 48% of patients taking Sustiva, AZT, and 3TC maintained HIV viral loads under 400 copies per milliliter of blood during the 3-1/2-year study; 43% had viral loads under 50 copies. This compares to 40% of those taking Sustiva, Crixivan, and 3TC who had viral loads under 400 copies; and 29% of those taking Crixivan, AZT, and 3TC who had viral loads under 400 copies. "With this new labeling, health care professionals now have additional information to draw on when creating a durable antiretroviral regimen for their treatment-naive patients," said Anthony Hooper, president of U.S. pharmaceuticals for BMS.

Advocate Magazine - KehlaniAdvocate Magazine - Gus Kenworthy

From our Sponsors

Most Popular

Latest Stories